Long-Term Outcomes of Enfortumab Vedotin vs Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma
Ann. Oncol 2023 Sep 05;[EPub Ahead of Print], JE Rosenberg, T Powles, GP Sonpavde, Y Loriot, I Duran, JL Lee, N Matsubara, C Vulsteke, D Castellano, R Mamtani, C Wu, M Matsangou, M Campbell, DP PetrylakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.